Novo Nordisk (NVO) closed at $62.89 in the latest trading session, marking a -1.7% move from the prior day. This change lagged the S&P 500's daily gain of 0.41%. Elsewhere, the Dow lost 0.83%, while the tech-heavy Nasdaq added 0.91%.
The drugmaker's stock has climbed by 24.31% in the past month, exceeding the Medical sector's loss of 0.74% and the S&P 500's gain of 0.38%.
Market participants will be closely following the financial results of Novo Nordisk in its upcoming release. The company plans to announce its earnings on February 4, 2026. On that day, Novo Nordisk is projected to report earnings of $0.89 per share, which would represent a year-over-year decline of 2.2%. In the meantime, our current consensus estimate forecasts the revenue to be $11.96 billion, indicating a 2.38% decline compared to the corresponding quarter of the prior year.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $3.57 per share and a revenue of $48.1 billion, signifying shifts of +8.84% and 0%, respectively, from the last year.
Investors should also pay attention to any latest changes in analyst estimates for Novo Nordisk. These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. The Zacks Consensus EPS estimate has moved 5.9% lower within the past month. Novo Nordisk presently features a Zacks Rank of #4 (Sell).
In the context of valuation, Novo Nordisk is at present trading with a Forward P/E ratio of 19.43. This represents a premium compared to its industry average Forward P/E of 15.48.
The Large Cap Pharmaceuticals industry is part of the Medical sector. With its current Zacks Industry Rank of 199, this industry ranks in the bottom 19% of all industries, numbering over 250.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Novo Nordisk A/S (NVO): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
